首页 › 基金 › KVP Capital Advisors, LP › DRUG
KVP Capital Advisors, LP 对 DRUG 的持仓历史
BRIGHT MINDS BIOSCIENCES INC · 医疗保健
KVP Capital Advisors, LP 在 Q3 2026 的 13F 申报中披露持有 DRUG(BRIGHT MINDS BIOSCIENCES INC)31,813 股,市值约 US$1.6M,约占其申报组合的 1.30%,在其申报持仓中市值排名第 26 位。 KVP Capital Advisors, LP 最近 3 个申报季度中有 3 个季度披露了 DRUG 持仓,最早可追溯至 Q1 2026。
最后更新: 2026-11-16 · 来源: SEC EDGAR Form 13F-HR
KVP Capital Advisors, LP 对 DRUG 的持仓演变
KVP Capital Advisors, LP 于 Q1 2026 首次披露 DRUG 持仓:31,813 股(约 US$2.3M)。 在 3 次申报中,KVP Capital Advisors, LP 的持股数量始终未变。 最近一期申报(Q3 2026)显示持股 31,813 股、市值约 US$1.6M。
逐季持仓明细
| 季度 | 股数 | 金额 | 变化 |
|---|---|---|---|
| Q1 2026 | 31.81K | $2.32M | 新进 |
| Q2 2026 | 31.81K | $2.23M | 持有 |
| Q3 2026 | 31.81K | $1.58M | 持有 |
折线上的点按变动类型着色;缺失季度表示该季未申报持仓。
关于 DRUG 与 13F 数据
DRUG(BRIGHT MINDS BIOSCIENCES INC)属于医疗保健行业。我们追踪的基金中还有 64 只申报持有 DRUG,申报仓位最大的包括:Cormorant Asset Management, LP (US$63.2M), Vestal Point Capital, LP (US$38.3M), BRAIDWELL LP (US$34.0M)。 根据美国 SEC 规定,管理资产超过 1 亿美元的机构投资者须在每季度结束后 45 天内提交 13F 表,披露其美股多头持仓。该数据不包含空头、大部分期权及海外持仓,因此应将其视为季度快照而非实时仓位。
其它持有 DRUG 的基金
- Cormorant Asset Management, LP 900.00K 股 · $63.18M · Q2 2026
- Vestal Point Capital, LP 545.00K 股 · $38.26M · Q2 2026
- BRAIDWELL LP 483.82K 股 · $33.96M · Q2 2026
- Vivo Capital, LLC 417.88K 股 · $20.82M · Q3 2026
- MPM BioImpact LLC 202.11K 股 · $14.19M · Q2 2026
- GREAT POINT PARTNERS LLC 109.60K 股 · $7.69M · Q2 2026
- Ikarian Capital, LLC 88.95K 股 · $6.24M · Q2 2026
- B Group, Inc. 95.00K 股 · $4.73M · Q3 2026
- ACUTA CAPITAL PARTNERS, LLC 93.15K 股 · $4.64M · Q3 2026
- Sio Capital Management, LLC 75.15K 股 · $3.74M · Q3 2026
- SUPERSTRING CAPITAL MANAGEMENT LP 48.05K 股 · $2.39M · Q3 2026
- Artia Global Partners LP 38.41K 股 · $1.91M · Q3 2026
更多关于 KVP Capital Advisors, LP
常见问题
How long has KVP Capital Advisors, LP held DRUG?
KVP Capital Advisors, LP has disclosed DRUG holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is KVP Capital Advisors, LP's current position in DRUG?
As of Q3 2026, KVP Capital Advisors, LP holds 31.81K shares of DRUG (BRIGHT MINDS BIOSCIENCES INC), valued at $1.58M, representing 1.30% of its reported portfolio and ranking #26.
Has KVP Capital Advisors, LP been buying or selling DRUG?
In the latest 13F filing (Q3 2026), KVP Capital Advisors, LP held unchanged its position in DRUG.
Which other funds hold DRUG?
Other major institutional holders of DRUG include Cormorant Asset Management, LP, Vestal Point Capital, LP, BRAIDWELL LP, among 64 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.